ArticleBioMed research international2026
Galectin-1, Adiponectin, Leptin, and the Adiponectin to Leptin Ratio as Predictors of Metabolic Syndrome: Influence of Age and Body Mass Index.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Galectin-1, Adiponectin, Leptin, and the Adiponectin to Leptin Ratio as Predictors of Metabolic Syndrome: Influence of Age and Body Mass Index.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic syndrome (MetS) is a multifactorial condition linked to adipose tissue dysfunction and insulin resistance. Emerging evidence highlights the potential roles of adipokines leptin, adiponectin, and galectin-1 in its pathogenesis. However, studies examining these biomarkers as predictors of MetS, particularly in the context of age and body mass index (BMI), remain limited and inconsistent.
objectiveThe objective of this study is to evaluate the association of serum galectin-1, leptin, adiponectin, and the adiponectin/leptin ratio (A/L) with MetS, and to identify their predictive value across different age and BMI groups.
methodsIn this prospective cross-sectional study, 122 participants were enrolled and categorized into MetS (n = 48) and healthy control (n = 74) groups based on NHLBI/AHA criteria. Anthropometric, clinical, and biochemical parameters were recorded. Serum levels of galectin-1, leptin, and adiponectin were measured, and the A/L was calculated. Participants were stratified by age (20-39 vs. ≥ 40 years) and BMI (normal, overweight, and obese). Group comparisons, correlation analysis, and binary logistic regression were conducted.
resultsGalectin-1 and adiponectin levels were significantly lower in the MetS group, whereas leptin levels were not significantly higher. The A/L ratio was significantly lower in the MetS group, particularly among middle-aged and obese individuals (p = 0.004). Galectin-1 correlated positively with adiponectin and the A/L ratio. In logistic regression analysis, A/L emerged as the only independent predictor, with each unit increase reducing the odds of MetS by 8.3%, whereas BMI was a consistent predictor across age groups.
conclusionGalectin-1, adiponectin, and the A/L ratio are associated with MetS, with the A/L serving as a robust independent predictor. These findings underscore the importance of adipokine profiling, particularly in stratified age and BMI groups, for early identification of metabolic risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.